Table 1.
Major findings of lipidomics-based epidemiological studies of CVDs
| Study Reference, Cohort | Platform | Samples | Lipids analysed |
|---|---|---|---|
| Ceramides as prognostic markers | |||
| Sigruener et al. [50], LURIC study | Shotgun MS | 3316 (768 incident CVD; 484 mortality) | 38 PCs, 15 LPCs, 30 PC Os, 31 PEs, 24 PE Os, 33 SMs, 7 Cers |
| Cheng et al. [51], ATHEROREMO-IVUS | LC–MS | 581 (underwent angiography) | 8 lipids (CEs and Cers) identified in LURIC study |
| Laaksonen et al. [52], Corogene, SPUM-ACS, BECAC | LC–MS | 3377 (mostly CVD patients) | 4 Cers (C16:0, C18:0, C24:0, C24:1) |
| Havulinna et al. [54], FINRISK2002 | LC–MS | 8101 healthy subjects (813 incident MACE) | 4 Cers (C16:0, C18:0, C24:0, C24:1) |
| Wang et al. [53], PREDIMED | LC–MS | 1017 (230 incident cases; 787 random samples) | 4 Cers (C16:0, C22:0, C24:0, C24:1) |
| Anroedh et al. [46], ATHEROREMO-IVUS | Shotgun MS | 581 (underwent angiography) | 10 lipids (CEs and Cers) identified in LURIC study |
| Alshehry et al. [55], ADVANCE | Targeted LC–MS | 3779 (case–control) | Lipidome-wide (310 lipid species) |
| Paynter et al. [56], WHI, PREDIMED | LC–MS | 944 (472 incident CHD; 472 controls); 627 (312 incident CHD; 315 controls) | Lipidome-wide (217 lipids) |
| Poss et al. [57], Utah population | LC–MS/MS | 674 (462 CAD patients; 212 controls) | 32 Sphingolipids |
| Opposite effects of MUFA and PUFA containing phospholipids | |||
| Sigruener et al. [50], LURIC study | Shotgun MS | 3316 (768 incident CVD; 484 mortality) | 38 PCs, 15 LPCs, 30 PC Os, 31 PEs, 24 PE Os, 33 SMs, 7 Cers |
| Alshehry et al. [55], ADVANCE | Targeted LC–MS | 3779 (case–control) | Lipidome-wide (310 lipid species) |
| Wang et al. [69], PREDIMED | LC–MS | 1017 (230 incident CVD; 787 random samples) | Lipidome-wide (200 lipids) |
| Wurtz et al. [36], FINRISK, SABRE, BWHHS | Targeted NMR metabolomics | 7256 (800 CVD events); 2622 (573 CVD events); 3563 (368 CVD events) | 14 lipoprotein subclasses and fatty acid composition |
| Razquin et al. [68], PREDIMED | LC–MS | 983 (case–control) | Lipidome-wide (202 lipids) |
| Mundra et al. [66], LIPID, ADVANCE | LC–MS | 5991; 3779 | Lipidome-wide (342 lipids) |
| TG species and risk of CVDs | |||
| Fernandez et al. [47], MDC study | Shotgun MS | 427 (211 incident CVD; 216 controls) | 85 lipids (TGs, DGs, CEs, SMs, PC Os, LPCs, PEs, PE Os) |
| Stegemann et al. [65], Bruneck study | Shotgun MS | 685 (90 incident CVD) | 135 lipids (PCs, LPCs, CEs, SMs, PSs, PEs, LPEs, TGs) |
| Alshehry et al. [55], ADVANCE | Targeted LC–MS | 3779 (case–control) | Lipidome-wide (310 lipid species) |
| Razquin et al. [68], PREDIMED | LC–MS | 983 (case–control) | Lipidome-wide (202 lipids) |
| Wang et al. [69], PREDIMED | LC–MS | 1017 (230 incident CVD; 787 random samples) | Lipidome-wide (200 lipids) |
CAD coronary artery disease, CE cholesteryl ester, Cer ceramide, CHD coronary heart disease, DG diacylglyceride, LPC lysophosphatidylcholine, LPE lysophosphatidylethanolamine, LC–MS liquid chromatography–mass spectrometry, MACE major adverse cardiovascular event, MS mass spectrometry, NMR nuclear magnetic resonance, PC phosphatidylcholine, PC O phosphatidylcholine–ether, PE phosphatidylethanolamine, PE O phosphatidylethanolamine–ether, SM sphingomyelin, TG triacyglycerol